Pegvisomant

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

Acromegaly Combination Treatment Study

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Strict IGF-1 Control in Acromegaly

Bone MicroArchitecture in Acromegaly

Effect of DPP4 Inhibition on Growth Hormone Secretion

Tissue Biomarker for Pegvisomant Action

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting

Pasireotide LAR and Pegvisomant Study in Acromegaly

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant

The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons

Long Term Study With B2036-PEG

Pegvisomant And Sandostatin LAR Combination Study